Brief

The document outlines options for manufacturers and GxP laboratories during the COVID-19 pandemic, when service personnel or external engineering support may not be able to operate as normal. Options include remote supervision by phone or video call, electronic approval and documentation, and off-site calibration/maintenance for manoeuvrable equipment. In cases where remote supervision is not possible, a quality system record should be raised and the delay to calibration or maintenance tasks risk assessed, considering criticality, frequency, and performance checks. The goal is to maintain compliance status and perform tasks at the earliest opportunity when restrictions are lifted.

This content is restricted.

Highlights content goes here...

This content is restricted.

Medicines and Healthcare products Regulatory Agency (MHRA)

Quick Insight
RADA.AI
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Enter your registered username/email id.

Enter your Email

Enter your email id below to signup.
Individual Plan
$125 / month OR $1250 / year
Features
Best for: Researchers, Legal professionals, Academics
Enterprise Plan
Contact for Pricing
Features
Best for: Law Firms, Corporations, Government Bodies